Table 1.
Patient characteristics
| Characteristic | Number (%) |
|---|---|
| All patients | 341 (100) |
| Median age, years (range) | 62 years (18–95) |
| Gender | |
| Female | 141 (41) |
| Male | 200 (59) |
| Histology | |
| PTCL-NOS | 107 (31) |
| ALCL, ALK + | 23 (7) |
| ALCL, ALK− | 43 (13) |
| ALCL, ALK unknown | 22 (6) |
| AITL | 77 (23) |
| NK/TCL | 23 (7) |
| ATLL | 20 (6) |
| EATCL | 10 (3) |
| SPTCL | 7 (2) |
| t-CTCL | 4 (1) |
| HSTCL | 5 (1) |
| History of CAD | 42(13) |
| History of DM | 45 (13) |
| History of prior malignancy | 11 (3) |
| Median BMI (range) | 26.2 (13.6–55.2) |
| B symptoms | 154 (47) |
| Performance status | |
| 0 | 117 (34) |
| 1 | 102 (30) |
| 2 | 40 (12) |
| 3 | 25 (7) |
| 4 | 5 (2) |
| NA | 52 (15) |
| Bone marrow involvement | 99 (29) |
| Nonmarrow extranodal diseasea | 168 (49) |
| Extranodal involvement >1 site | 61 (18) |
| Ann Arbor stage | |
| I | 47 (14) |
| II | 39 (11) |
| III | 77 (23) |
| IV | 165 (48) |
| NA | 13 (4) |
| Elevated LDH | 141 (41) |
| Anemia <11.0 g/dl | 170 (50) |
| Platelets <150 × 109/l | 92 (27) |
| Renal insufficiency | 42 (12) |
| Hypoalbuminemia | 119 (35) |
| Bulk >7 cm | 26 (9) |
| IPI score (n = 254) | |
| 0–1 | 82 (32) |
| 2 | 71 (28) |
| 3–5 | 101 (40) |
| PIT score (n = 233) | |
| 0–1 | 115 (49) |
| 2 | 67 (29) |
| 3–4 | 51 (22) |
| IPTCLP score (n = 249) | |
| 0 | 83 (33) |
| 1 | 87 (35) |
| 2–3 | 79 (32) |
| Initial systemic treatment (n = 341) | |
| CHOP-like | 237 (70) |
| HyperCVAD/MA | 20 (6) |
| Other regimenb | 61 (18) |
| Palliative care only | 23 (7) |
| SCT in first remission (n = 318) | |
| Yes | 33 (10) |
| No | 285 (90) |
| Radiation in first remission (n = 318) | |
| Yes | 68 (21) |
| No | 250 (79) |
aMost common sites: skin 26%, liver 13%, lung 12%, nasal/sinus 10%, GI tract 9%, subcutaneous tissue 8%, bone 7%, CNS 4%, and breast 3%.
bOther regimens were administered to fewer than 10 patients each.
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; ALCL, anaplastic large-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; NK/TCL, NK/T-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; EATCL, enteropathy-associated T-cell lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; HTCL, hepatosplenic T-cell lymphoma; t-CTCL, transformed cutaneous T-cell lymphoma; NA, not available; CAD, coronary heart disease; DM, diabetes mellitus; BMI, body mass index; LDH, lactate dehydrogenase; IPI, International Prognostic Index; PIT, Prognostic Index for T-cell lymphoma; IPTCLP, International peripheral T-cell lymphoma Project score; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; hyperCVAD/MA, hyperfractionated cyclophosphamide, vincristine, dexamethasone, doxorubicin/ methotrexate, cytarabine; SCT, stem-cell transplantation.